Image Credit: Canva
When was the last time you measured your waistline? If you assume that BMI is the only number to focus on when it comes to your health, think twice. New research has revealed a shocking revelation—your waist circumference might be a far better predictor of men's cancer risk than BMI.
The study finds that for each 4-inch increase in waist size, a man's risk of cancer increases by a staggering 25%. Meanwhile, BMI, commonly regarded as the gold standard for assessing obesity, raises cancer risk by only 19% for the same weight gain. So, if you've been dismissing that pesky belly fat, it's time to take notice.
But why is your waistline so important? The reason is visceral fat—the hidden, deep fat that accumulates around your organs. Unlike other body fat, visceral fat is a stealthy troublemaker, causing inflammation, insulin resistance, and abnormal blood fat levels—all of which combine to create a cancer-perfect storm.
Obesity has been associated with an increased risk of numerous health conditions, including cancer, for decades. The research, though, indicates that a specific measure of the body—waist circumference—may be an even more reliable forecaster of cancer risk in men than the more frequently employed Body Mass Index (BMI). This finding emphasizes the need to pay particular attention to the distribution of fat and not merely to the weight of the body.
BMI has been the go-to measure for years for gauging health risks related to obesity. New research, though, that appears in The Journal of the National Cancer Institute indicates that waist measurement is a better predictor of cancer risk in men. According to the research, four more inches (10 cm) around the waist will add 25% to a man's cancer risk. Conversely, a 3.7 kg/m² rise in BMI (from a BMI of 24 to 27.7) increased cancer risk by only 19%.
Why is waist circumference a better predictor, then? Unlike BMI, which measures weight relative to height, waist circumference actually measures abdominal fat—specifically, visceral fat. This type of fat encircles internal organs and is also linked to higher levels of inflammation, insulin resistance, and abnormal blood lipids, all of which are factors in cancer growth. BMI, however, does not measure fat distribution, so two individuals with the same BMI can have very different levels of health risk depending on where fat is deposited on their bodies.
Interestingly, the research identified a significant difference between men and women when it came to waist circumference and cancer risk. Although waist circumference and BMI were linked with obesity-related cancers in women, the relationship was weaker than for men. An increase of 12 cm (4.7 inches) in waist size or a 4.3 rise in BMI (from 24 to 28.3) raised the cancer risk in women by just 13%—a much lower percentage than for men.
Experts credit this difference to the way that fat is stored in the body. Men are more likely to carry fat around the abdomen, especially as visceral fat, which is more metabolically active and associated with cancer-producing biological alterations. Women, by contrast, store fat in peripheral sites such as the hips and thighs, where it is less likely to drive systemic inflammation and metabolic disturbances.
A possible reason is that men tend to depot fat more in the visceral regions, whereas women tend to carry more subcutaneous and peripheral fat," wrote the researchers. "This may render waist circumference a more robust risk factor for cancer in men and account for why waist circumference provides additional risk information beyond BMI in men but not women."
The research used the International Agency for Research on Cancer (IARC) data to define obesity-related cancers. These cancers are esophageal (adenocarcinoma), gastric (cardia), colorectal, rectal, liver, gallbladder, pancreatic, renal, and thyroid cancers, and multiple myeloma and meningioma. In men, abdominal obesity is especially significant in raising the risk of these cancers through high levels of insulin and markers of inflammation.
For women, the research proposes that both waist circumference and hip circumference may give a more accurate estimate of visceral fat and cancer risk. "Adding hip circumference to risk models could strengthen the link between waist circumference and cancer, especially in women," researchers observed.
With these results, doctors advise men to be more mindful of their waistline than only their BMI. Waist size is an easy method to gauge health risk, and its maintenance through lifestyle changes might be the key to cancer prevention.
Track Your Waist Size: Regularly measure your waist circumference and try to keep it in a healthy range (below 40 inches for men, according to medical advice).
Eat a Balanced Diet: A diet containing high fiber, lean protein, and healthy fats can assist in limiting visceral fat gain.
Exercise Consistently: Regular exercise with a combination of aerobic and strength training will help maintain a healthy waistline.
Control Stress and Sleep: Persistent stress and inadequate sleep tend to cause weight gain, especially in the midsection of the body.
Regular Health Screenings: Early identification of cancer risk factors through regular screening can greatly enhance long-term health status.
Pancreatic cancer, which is notoriously difficult to catch early, can now be detected early with a simple blood test, but powered by artificial intelligence (AI).
The AI-based test analyzes metabolic fingerprints in a blood sample and spots pancreatic cancer at its earliest stages with up to 94 percent accuracy.
The study published in the journal Nature Communications showed that the diagnostic tool called PanMETAI can be a non-invasive and cost-effective screening tool to save lives lost due to pancreatic cancer -- one of the deadliest forms of cancer worldwide, with only a 13 percent five-year survival rate.
The tool combines with nuclear magnetic resonance (NMR) metabolomics to identify pancreatic cancer with remarkable accuracy. NMR is a method that captures the unique chemical fingerprint of hundreds of metabolites in a patient's blood.
"By combining the power of AI with the rich metabolic information captured by NMR spectroscopy, we have created a tool that can detect pancreatic cancer at its earliest and most treatable stages. Our goal is to bring this technology to clinical practice so that more patients can benefit from timely diagnosis and treatment," said Yu-Ting Chang, Professor of internal medicine (gastroenterology and hepatology) at National Taiwan University, Taiwan.
The researchers noted that the PanMETAI platform enables high-precision pancreatic cancer prediction, facilitating early detection, which will enhance treatment outcomes.
Pancreatic cancer is hard to treat as the symptoms are rarely seen in the initial stages, and most patients receive their diagnosis at an advanced stage, when treatment options are limited.
The PanMETAI platform tapped the current screening methods -- blood marker CA19-9 -- for early detection.
Using 500 microliters of blood serum, the platform was able to extract over 260,000 metabolic signals in the study. It then analyzed the datasets using an AI model.
By integrating these metabolic profiles with age, the cancer marker CA19-9, and a protein biomarker called Activin A, PanMETAI correctly distinguished cancer patients from high-risk controls in nearly every case, said the team.
The researchers then validated the model in an independent Lithuanian cohort of 322 participants. The results proved that the tool works reliably across diverse populations.
Further, the team found that NMR metabolomic data were essential to boost early-stage detection sensitivity.
These capture subtle metabolic shifts -- such as decreased HDL cholesterol (bad cholesterol) and glutamine (an essential protein), and elevated lactic acid, glucose, and glutamic acid -- that occur before the cancer becomes clinically apparent.
Pancreatic cancer is the 12th most common cancer worldwide.
Data from the Globocan reveal there were 510,992 new cases of pancreatic cancer in 2022, with China, the US, and Japan reporting the highest number of cases.
The pancreas is a 15cm long gland found behind the stomach and in front of the spine. The organ is key to digesting food and curbing blood sugar levels in the body.
Cancer develops in the pancreas when a change in the cells of the organ causes them to grow uncontrollably. Most pancreatic cancers start in exocrine cells, which produce digestive enzymes to help digest food and are secreted into the small intestine.
While there are hardly any early symptoms, the ones appear can include:
Credits: Canva
Rates of binge drinking have raised among gen Z since their teenage years. As per a recent research by the UCL Centre for Longitudinal Studies (CLS), data from nearly 10,000 people born across the UK in 2000-02 who are taking part in the Millennium Cohort Study was analyzed. The research found that the gen Z is challenging their reputation as the "generation sensible".
The study found that 7 in 10, which is 63 per cent of 23-year-olds report binge drinking in the past year.
Nearly a third or around 29 per cent also said they did so at least monthly, which is up from 10 per cent at age 17.
The study also found that while drug use is relatively limited in the teenage years, by 20, almost half of them, or 49 per cent have used cannabis and a third, around 32 per cent have tried harder drugs like cocaine, ketamine and ecstasy.
Researchers compared substance use in the same group at ages 17 and 23. By 23, the share reporting binge drinking at least once in the past year rose by 15 percentage points, from 53% at 17 to 68%. Binge drinking refers to consuming six or more alcoholic drinks in one sitting.
Drug use among Gen Z has increased substantially as they move from their teenage years into their early 20s. The share of young people who said they had tried cannabis rose by 18 percentage points between ages 17 and 23, climbing from 31 per cent to 49 per cent.
Use of harder drugs showed an even steeper rise. The proportion of young people who said they had experimented with harder substances more than tripled, increasing from 10 per cent at 17 to 32 per cent by the age of 23. Meanwhile, the number who reported using these drugs at least 10 times in the past year went up from 3 percent to 8 percent.
The study also examined other potentially addictive behaviors. Nearly a third of the group, about 32 per cent, reported gambling by the age of 23. However, only 4 percent described their gambling as problematic.
Vaping saw one of the most noticeable increases. Daily vaping rose sharply from 3 percent at age 17 to 19 per cent by age 23. In comparison, cigarette smoking remained relatively stable, increasing slightly from 8 per cent to 9 percent.
Lead author Dr Aase Villadsen said the findings challenge the common belief that younger generations are moving away from alcohol.
She explained that while recent reports have suggested Gen Z drinks less than earlier generations, the new study indicates that this may not hold true once some members of this generation reach their early 20s.
Although late adolescence and early adulthood are often periods of experimentation, Villadsen said the rise in binge drinking and drug use during the early 20s is concerning, especially if these behaviors begin to become long-term habits.
She noted that the sharp increase in these behaviors between adolescence and early adulthood highlights how risks can intensify during this stage of life.
Villadsen also stressed that prevention strategies should focus on groups that appear to be more vulnerable. For instance, young men were found to be about seven times more likely than women to report gambling problems and were also more likely to use harder drugs.
Dr Katherine Severi, chief executive of the Institute of Alcohol Studies, as reported by The Guardian, said young people are particularly vulnerable to alcohol’s effects because the brain continues to develop until the mid-20s.
She said it is worrying that despite frequent claims that younger generations drink less, the findings suggest that Gen Z drinkers in their early 20s may be consuming alcohol at similar or even higher levels than millennials did at the same age.
Severi also pointed to higher rates of heavy drinking among university students as a major concern. According to her, this reflects the influence of the broader alcohol environment rather than individual choices alone.
She explained that affordability, easy availability and heavy promotion of alcohol are major drivers of alcohol-related harm, and students are often exposed to all three.
Severi added that universities have a responsibility to ensure students can study and live in a safe environment. She also said commercial ties with alcohol companies, such as sponsorships of sports clubs or campus events, should not take priority over student health and wellbeing.
The findings come from Substance Use and Addictive Behaviours: Initial Findings From the Millennium Cohort Study at age 23, a briefing paper by Aase Villadsen and Emla Fitzsimons that will be published on the CLS website.
Credits: Wikimedia Commons
The United States has signed 24 bilateral health Memoranda of Understanding or MoUs with Latin America and African countries under the Trump administration's America First Global Health Strategy.
The first agreement with Panama is described as “strengthening Western hemisphere health security”, which it added is “a priority”. Thereafter, four Latin American agreements too involve smaller grants and focus on disease surveillance. Other 20 agreements all with African countries who have been previous recipients of health grants via the now disbanded US agency for International Development or USAID and decimated US President's Emergency Funds for AIDS Relief (PEPFAR).
The five-year MoUs aim to quickly shift financial responsibility for key health services to national governments. In several countries, including Kenya, Uganda and the Democratic Republic of Congo (DRC), more than half of HIV programme funding has traditionally come from donors, particularly the United States. In the DRC, for instance, at least half of the antiretroviral medicines used have been financed by the US.
The transitional Memorandums of Understanding (MoUs) signed between the United States and several countries come with a major condition. They require strong investment in infectious disease surveillance systems.
The goal is to ensure that pathogen information from outbreaks is shared with the US within a week. Officials say this helps detect global threats early and protect public health.
At the same time, it gives US pharmaceutical companies early access to pathogen data, allowing them to develop vaccines, medicines and diagnostics more quickly.
The United States and the Democratic Republic of Congo (DRC) signed their health MoU on 26 February. According to the US State Department, the agreement focuses on strengthening the country’s ability to detect and contain infectious disease outbreaks before they spread internationally.
Under the agreement:
Most of the funding will support a national integrated surveillance and outbreak response system.
The MoU also aims to modernize health data systems through electronic medical records, interoperable platforms, better trained community health workers and expanded services for HIV, tuberculosis, malaria, polio and maternal and child health.
In several cases, health agreements were preceded by deals related to natural resources.
The United States and the DRC first signed a strategic partnership on critical minerals. The deal aims to secure supplies of minerals needed for commercial and defense industries.
The DRC is one of the world’s largest sources of rare earth minerals, including cobalt and copper. China has historically dominated the purchasing and processing of these resources.
Recently, the DRC has begun opening its mineral sector to US investors. According to Reuters, the government sent Washington a shortlist of state owned assets involving:
Guinea followed a similar path. It signed a minerals MoU with the US on 5 February, followed by a health MoU on 27 February. The health agreement prioritizes strengthening laboratory networks and improving biosafety standards by 2027.
Not all countries are comfortable linking health support to access to resources or data.
In the DRC, a group of lawyers has challenged the minerals agreement in the Constitutional Court. They argue that the deal violates the constitution and undermines national sovereignty over natural resources.
Zimbabwe also withdrew from negotiations with the US over a similar agreement.
Officials said the country was asked to share biological resources and outbreak data for years without any guarantee that vaccines, treatments or diagnostics developed from that data would be available to Zimbabwe if a future crisis occurred. They also said the US did not offer reciprocal sharing of its own epidemiological data.
Kenya’s agreement with the United States has also faced legal hurdles. The country’s High Court halted the MoU after two court challenges questioned provisions that could allow the US access to patient data and pathogen information.
Zambia has also expressed reservations about its proposed health deal with Washington. The agreement stalled after the US linked the billion dollar package to cooperation in the country’s mining sector, particularly copper and cobalt.
Zambia has since asked for revisions, saying parts of the deal do not align with its national interests.
Some experts argue that these agreements reflect a broader shift in US global health policy.
Sophie Harman, professor of international politics at Queen Mary University of London, wrote in the BMJ that extraction appears to be central to the approach.
According to her analysis, the policy focuses less on improving global health outcomes and more on strengthening US economic and geopolitical interests, including competition with China.
She warns that countries entering such agreements could risk giving up resources or scientific data while gaining relatively limited health benefits.
© 2024 Bennett, Coleman & Company Limited